Новости медицины портала Remedium.ru - самая актуальная информация о рынке лекарств и медицинского обеспечения

Опрос для врачей

  1. Пользуетесь ли вы интернетом на работе?

Вход на сайт

Авторизоваться
Логин:
Пароль:
Регистрация
Забыли свой пароль?

Facebook

Вакансии фармкомпанийФармрынок

Реклама




Главная / Врачам

11.07.2018

Антагонисты минералокортикоидных рецепторов. Новые расширенные возможности для кардио и нефропротекции

13. Young M, Head G, Funder JW. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol, 1995, 269: E657-E662.

14. Stier CT. Eplerenone: a selective aldosterone blocker. Cardiovasc Drug Rev, 2003, 21(3): 169-84. 10.1111/j.1527-3466.2003.tb00114.x

15. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci, 2002, 970: 89-100.

16. Карабаева А.Ж., Есаян А.М., Каюков И.Г. Влияние полиморфизма гена альдостерон-синтазы на концентрацию альдостерона плазмы, функцию эндотелия, величину артериального давления и состояние миокарда левого желудочка у больных с хронической болезнью почек. Вестник Санкт-Петербургского университета, 2008, 1(серия 11): 24-31

17. Mortensen LA, Bistrup C, Thiesson HC. Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity? Front Med, 2017, 4: 210. doi: 10.3389/fmed.2017.00210.

18. Карабаева А.Ж. Дисфункция эндотелия в патогенезе сердечно-сосудистых заболеваний. Терапевтический вестник, 2006, 3(11): 22-27

19. Funder JW. Minireview: aldosterone and miner-alocorticoid receptors: past, present, and future. Endocrinology, 2010, 151(11): 5098-5102.

20. Карабаева А.Ж., Есаян А.М., Каюков И.Г. и соавт. Влияние спиронолактона на гипертрофию миокарда левого желудочка у крыс генетической линии Wistar с экспериментальной уремией. Бюллетень экспериментальной биологии и медицины, 2008, 6: 659-663

21. Guichard JL, Clark D III, Caloun DA. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag, 2013, 9: 321-31.

22. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension, 2005, 46: 1227-1246.

23. Ponda MP, Hostetter ThH. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol, 2006, 1: 668-667.

24. Galuppo P, Bauersachs J. Mineralocorticoid receptor activation in myocardial infarction and failure: Recent advances. Eur J Clin Invest, 2012, 42: 1112-1120.

25. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol, 2012, 350: 266-272.

26. Roger VL. Epidemiology of Heart Failure. Circ Res, 2013 August 30, 113(6): 646-659.

27. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol, 2005, 16: 489-95.

28. Parfrey PS, Harnett JD, Foley RN. Heart failure and ischemic heart disease in chronic uremia. Curr Opin Nephrol Hypertens, 1995, 4: 105-10.

29. Pitt B, Zannad F, Remme WJ,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.N Engl J Med, 1999 Sep 2, 341(10): 709-17.

30. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003, 348: 1309-1321.

31. Zannad F, McMurray JJ, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail, 2010, 12: 617-622.

32. Rossi GP et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension, 2013, 62: 62-69.

33. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013, 128: e240-e327.

34. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2):a randomised, double-blind, crossover trial. Lancet, 2015, 386: 2059-2068.

35. Piontkowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2016, 37(27): 2129-2200.

36. Juurlink DN, Mamdani MM, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med, 2004, 351:543-51.

37. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant. 2003, 18: 1814-1819.

38. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med, 2001, 110: 438-441.

39. Lauren B. Cooper, MD, MHS, Steven J. Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. JAHA, 2017, 6: e006540. DOI: 10.1161/JAHA.117.006540.

40. Dahal K, Kunwar S, Rijal J et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of random-ized and nonrandomized studies. Am J Hypertens, 2015. DOI: 10.1093/ajh/hpv031.

41. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplere-none reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol, 2006, 1: 940-951.

42. James PA, Oparil S, Carter BL et al. 2014 evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 2014, 311: 507-520.

43. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev, 2014, 4: Cd007004.

44. Rafiq K, Hitomi H, Nakano D, et al. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharmacol Sci, 2011, 115: 1-7.

45. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol, 2007 Sep, 3(9): 486-92.

46. Bomback AS, Kshirsagar AV, Klemmer PJ. Renal aspirin: will all patients with chronic kidney disease one day take spironolactone? Nat Clin Pract Nephrol, 2009, 5: 74-5.

47. Bomback AS, et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis, 2008, 51: 199-211.

48. Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJю The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther, 2008, 10(1): R5.

49. Saran R, Li Y, Robinson B et al. US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis, 2015, 66: Svii(S1-S305).

50. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D and Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int, 1995, 47: 884-890.

51. Есаян А.М., Карабаева А.Ж., Каюков И.Г. Кандинская М.И. Ассоциация полиморфизма гена альдостеронсинтазы с концентрацией альдостерона плазмы, артериальной гипертензией и ремоделированием миокарда у больных на программном гемодиализе. Нефрология, 2007, 11(3): 48-52./

52. Есаян А.М., Зарипова И.В. Эффективность и безопасность блокаторов рецепторов ангиотензина II у диализных пациентов. Нефро логия, 2010, 14(3): 13-16




Ключевые слова: альдостерон, антагонисты минералокортикоидных рецепторов, сердечная недостаточность, хроническая болезнь почек, диализ, трансплантация почки, aldosterone, mineralocorticoid receptor antagonists, heart failure, chronic kidney disease, dialysis, kidney tran
 

Последние статьи

Мероприятия

     2018
След. год

Пн Вт Ср Чт Пт Сб Вс
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 1 2


Подписка


Реклама


Мы в Twitter

Фармацевтам